Breaking News
Sort by:
Top Post
Novalis Biotech Invests in Ultra Sensitive Genomics Technology by Rarity Bioscience
Rarity Bioscience announces a new strategic investment from Belgium-based Novalis Biotech. The investment is facilitated […]
IMPLICITY Raises $23M to Broaden Use of Its Cardiac Remote Monitoring Platform
IMPLICITY ®,a, leader in remote patient monitoring and cardiac data management solutions, today announced it […]
RVAC Medicines, a CBC-Incubated mRNA Platform Company, Raises US$140 Million to Expand R&D and Manufacturing Capacity
RVAC Medicines Pte. Ltd. (“RVAC”), an emerging messenger RNA (mRNA) platform company incubated in Singapore by CBC […]
Pheast Raises $76M in Series A Funding to Train the Immune System to Feast on Cancer
Pheast Therapeutics, a company developing novel checkpoint therapies to fight cancer, today announced it has […]
Epitopea Announces $14 Million Financing to Advance Cancer Immunotherapeutics
Epitopea, a transatlantic cancer immunotherapeutics company and global leader in exploiting a new class of […]
MitoRx Therapeutics Announces Seed Financing to Advance its Mitochondrial-Protective Therapeutics to Treat Degenerative Diseases
MitoRx Therapeutics (MitoRx), a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction to arrest […]
Ribonexus Receives €2M in Deep Tech Financing from Bpifrance
Ribonexus, a biotechnology start-up developing new therapies that can overcome resistance to current targeted therapies […]
Viz.ai Raises $100 Million in Series D Funding, Led by Tiger Global and Insight Partners at $1.2 Billion Valuation
Viz.ai, the leading AI-powered disease detection and care coordination platform, has raised a $100 million […]
Rona Therapeutics Announces Completion of $33 Million Series A Financing to Advance Global Discovery and Development of RNA Therapeutics
Rona Therapeutics, a fully integrated platform company dedicated to the discovery, development and manufacturing of […]
Kynos Therapeutics Emerges from Stealth with £9 Million Financing and Phase 1-ready KMO Inhibitor
Kynos Therapeutics Ltd (Kynos or the Company), an immune-metabolic company with world-leading expertise in the […]
ENSEM Therapeutics, a CBC Group-Incubated Biopharma Company, Raises $67 Million in Series A Financing to Develop Small Molecule Medicines for Difficult-to-Drug Targets
ENSEM Therapeutics Inc. (ENSEM), a Boston-based biotechnology company focusing on high value and difficult-to-drug oncology targets, […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more